Skip to content

Analgesic efficacy of interpleural and paravertebral block

A comparison of the analgesic efficacy of interpleural and ultrasound guided thoracic paravertebral block for mastectomy: a double blinded randomised trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13324055
Enrollment
70
Registered
2014-11-10
Start date
2015-01-01
Completion date
Unknown
Last updated
2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia for mastectomy Surgery

Interventions

1. Group one will receive ultrasound guided paravertebral block and a standardised anaesthetic 2. Group two will receive interpleural block and the same standardised anaesthetic

Sponsors

The Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Female patients 2. Between the age of 18 and 85 3. Undergoing elective mastectomy at the RVI

Exclusion criteria

Exclusion criteria: 1. Any procedure other than sentinel node biopsy in addition to simple mastectomy. This includes axillary node clearance and reconstructions. 2. BMI>35 3. Musculoskeletal deformity 4. Local infection at paravertebral or interpleural injection site 5. Coagulopathy 6. Respiratory disease which limits functional capacity 7. Neurological disease 8. Allergy or contraindication to local anaesthetics, opiates, paracetamol, parecoxib, volatile or intravenous anaesthetics and neuromuscular blockade. 9. Chronic pain treated by long term opiates 10. Psychiatric disease 11. Pregnancy or breast feeding 12. Patient refusal or incapacity 13. Anticipated difficult intubation which would preclude the use of neuromuscular blockade 14. Day case procedure planned

Design outcomes

Primary

MeasureTime frame
VAS pain score measured at six hourly intervals for the first 24 hours following mastectomy

Secondary

MeasureTime frame
1. Nausea and vomiting rate 2. 24-hour morphine consumption

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026